Idelalisib

4 trials 3 recruiting LOncology

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

3 Recruiting

1 Completed trials

4 Sponsors

13 Countries

Phase III

Phase II

Phase III: 3 Phase II: 1

Indications tested

B-cell small lymphocytic lymphoma 1 Colorectal cancer metastatic 1

Sponsors using this IMP

BeOne Medicines AG 1 Dizal (Jiangsu) Pharmaceutical Co. Ltd. 1 Loxo Oncology Inc. 1 Oslo University Hospital HF 1

All trials

4 total

A Phase 3 Study of DZD8586 versus Investigator’s Choice in r/r CLL/SLL Recruiting

2025-522669-32-00 Phase III 2 countries Dizal (Jiangsu) Pharmaceutical Co. Ltd.
A Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituxima… Recruiting

2024-518893-15-00 Phase III 5 countries BeOne Medicines AG
EVIDENT Recruiting

2023-510092-62-00 Phase II 1 country Oslo University Hospital HF
A Phase 3 Open Label, Randomized Study of LOXO 305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab … Ended

2023-507697-40-00 Phase III 11 countries Loxo Oncology Inc.

Showing 1–4 of 4 trials

← All drugs A–Z